ASR-3001

ASR-3001
臨床資料
其他名稱	ASR3001; 5-MeO-iPALT; 5-MeO-ALiPT; 5-Methoxy-N-isopropyl-N-allyltryptamine; 5-Methoxy-N-allyl-N-isopropyltryptamine
给药途径	Oral
藥物類別	Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC碼	未分配;
法律規範狀態
法律規範	In general Unscheduled;
藥物動力學數據
藥效起始時間（英语：Onset of action）	≤15 minutes (as fast as 6–8 minutes)
作用時間	1.5–2.5 hours
识别信息
	IUPAC命名法 N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine; ;
PubChem CID	166468733;
化学信息
化学式	C17H24N2O
摩尔质量	272.39 g·mol−1
3D模型（JSmol）	交互式图像;
	SMILES CC(C)N(CCC1=CNC2=C1C=C(C=C2)OC)CC=C;
	InChI InChI=1S/C17H24N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h5-7,11-13,18H,1,8-10H2,2-4H3; Key:MRWWDVFDOFUYKB-UHFFFAOYSA-N;

ASR-3001，又称5-甲氧基-N-异丙基-N-烯丙基色胺（5-MeO-iPALT）是一种血清素受體激動劑，属于色胺类迷幻药物，目前正在开发用于治疗精神障碍。^[5]^[1]^[2]^[3]它是5-MeO-DALT、5-MeO-DiPT和5-MeO-MiPT的结构类似物。^[6]

ASR-3001最初于2023年被报道，并于同年授予专利。^[1]^[6]

研究

截至2025年初，ASR-3001处于临床前研究阶段。^[7]

参考文献

^ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 Goldstein L. Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research. Benzinga. 10 July 2023 [19 April 2025].
^ ^2.0 ^2.1 Busby M. The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown. DoubleBlind Mag. 2 November 2023 [19 April 2025].
^ ^3.0 ^3.1 Busby M. What Happens When You Inherit 500 Psychedelic Compounds?. DoubleBlind Mag. 30 March 2025 [19 April 2025].
^ ^4.0 ^4.1 Joe Moore. Shulgin Farm and the Future of Psychedelic Drug Development (Featuring: Paul F. Daley, Ph.D.) (播客). Psychedelics Today. 事件发生在 16:12–20:45. 2 April 2024. Our most advanced compound right now is a tryptamine that's orally active, fast-onset, the latent period before you start to feel effects is as little as 6 to 8 minutes, relatively short-acting, 90 minutes to two and a half hours, and satisfyingly internally psychedelic as opposed to entactogenic. But interestingly no visual involvement. So there are no open-eyed, closed-eyed visuals, that aspect is just not present. [...] We think that there's probably a subset of patients who are, for whatever reason, reluctant to get into a full-immersion psychedelic experience, at least initially. So once they're more familiar with the territory, something like a psilocybin experience, something more intense and all-encompassing might be more easily tolerated if there are some training wheels in advance. So we think that compound has that role.
^ Delving into the Latest Updates on Tryptamine(ASRI) with Synapse. Synapse. 16 April 2025 [19 April 2025].
^ ^6.0 ^6.1 WO patent 2023034645A2,Paul Daley; Nicholas Cozzi & Wyeth Baillie Callaway,「Asymmetric allyl tryptamines」,发表于9 March 2023,指定于Alexander Shulgin Research Institute
^ Michael Haichin. Psychedelics Drug Development Tracker. Psychedelic Alpha. 2024 [29 January 2025].

外部链接

[Goldstein2023-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 Goldstein L. Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research. Benzinga. 10 July 2023 [19 April 2025].

[Busby2023-2] 2.0 ^2.1 Busby M. The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown. DoubleBlind Mag. 2 November 2023 [19 April 2025].

[Busby2025-3] 3.0 ^3.1 Busby M. What Happens When You Inherit 500 Psychedelic Compounds?. DoubleBlind Mag. 30 March 2025 [19 April 2025].

[MooreDaley2024-4] 4.0 ^4.1 Joe Moore. Shulgin Farm and the Future of Psychedelic Drug Development (Featuring: Paul F. Daley, Ph.D.) (播客). Psychedelics Today. 事件发生在 16:12–20:45. 2 April 2024. Our most advanced compound right now is a tryptamine that's orally active, fast-onset, the latent period before you start to feel effects is as little as 6 to 8 minutes, relatively short-acting, 90 minutes to two and a half hours, and satisfyingly internally psychedelic as opposed to entactogenic. But interestingly no visual involvement. So there are no open-eyed, closed-eyed visuals, that aspect is just not present. [...] We think that there's probably a subset of patients who are, for whatever reason, reluctant to get into a full-immersion psychedelic experience, at least initially. So once they're more familiar with the territory, something like a psilocybin experience, something more intense and all-encompassing might be more easily tolerated if there are some training wheels in advance. So we think that compound has that role.

[Synapse-5] Delving into the Latest Updates on Tryptamine(ASRI) with Synapse. Synapse. 16 April 2025 [19 April 2025].

[WO2023034645A2-6] 6.0 ^6.1 WO patent 2023034645A2,Paul Daley; Nicholas Cozzi & Wyeth Baillie Callaway,「Asymmetric allyl tryptamines」,发表于9 March 2023,指定于Alexander Shulgin Research Institute

[PsychedelicAlpha-Tracker-7] Michael Haichin. Psychedelics Drug Development Tracker. Psychedelic Alpha. 2024 [29 January 2025].

[1]

[2]

[3]

[4]

[5]

[6]

[7]